Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H29N5O6S.H2O |
Molecular Weight | 569.629 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.COC1=CC=CC=C1OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C3=CC=C(C=C3)C(C)(C)C)C4=NC=CC=N4
InChI
InChIKey=SXTRWVVIEPWAKM-UHFFFAOYSA-N
InChI=1S/C27H29N5O6S.H2O/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24;/h5-15,33H,16-17H2,1-4H3,(H,30,31,32);1H2
Bosentan is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer®. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. Bosentan competitively antagonizes the binding of 125I-labeled ET-1 to human vascular smooth muscle cells (predominantly
ETA receptors) with an inhibition constant (Ki )
of 4.7 nM and to human placenta membranes (predominantly
ETB receptors) with a Ki of 95 nM. Furthermore,
bosentan is specific for endothelin receptors and
does not interfere with the binding of a variety of peptides,
neurotransmitters, growth factors, or eicosanoids to their
receptors.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2096678 |
|||
Target ID: CHEMBL4566 |
4.7 nM [Ki] | ||
Target ID: CHEMBL1785 |
95.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TRACLEER Approved UseTracleer is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) (1.1). Considerations for use: Consider whether benefits offset the risk of hepatotoxicity in WHO Class II patients. Early hepatotoxicity may preclude future use as disease progresses (1.1). 1.1 Pulmonary Arterial Hypertension Tracleer® is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies (14.1) Launch Date2001 |
PubMed
Title | Date | PubMed |
---|---|---|
Influence of several methodological procedures utilized to obtain in vitro vascular preparations on endothelial activity. | 2001 |
|
Current management of primary pulmonary hypertension. | 2001 |
|
Pharmacological regulation of postischemic sinusoidal diameters in rats--a new approach for reducing hepatic ischemia/reperfusion injury. | 2001 |
|
Endothelin blockade in angiotensin II hypertension: prevention and treatment studies in the rat. | 2001 Dec |
|
Small bowel review: diseases of the small intestine. | 2001 Dec |
|
Pulmonary hypertension associated with COPD. | 2001 Dec |
|
Angiotensin II activates collagen type I gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-beta. | 2001 Dec |
|
Role of endogenous endothelin on coronary reflow after cardioplegic arrest. | 2001 Dec |
|
Endothelin antagonist reduces hemodynamic responses to vasopressin in DOCA-salt hypertension. | 2001 Dec |
|
Endothelin resets renal blood flow autoregulatory efficiency during acute blockade of NO in the rat. | 2001 Dec |
|
Coronary and aortic vasoreactivity protection with endothelin receptor antagonist, bosentan, after ischemia and hypoxia in aged rats. | 2001 Dec 7 |
|
New pharmacological strategies for the treatment of heart failure. | 2001 Jul |
|
[Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study]. | 2001 Nov |
|
Rationale and perspective of endothelin-1 antagonism in acute heart failure. | 2001 Nov |
|
Effects of the endothelin receptor antagonist bosentan on cardiac performance during porcine endotoxin shock. | 2001 Nov |
|
Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1. | 2001 Nov |
|
Endothelin-1 decreases glutamate uptake in primary cultured rat astrocytes. | 2001 Nov |
|
Endothelin-1, a regulator of angiogenesis in the chick chorioallantoic membrane. | 2001 Nov-Dec |
|
Endothelin receptor blockade and nitric oxide bioactivity. | 2001 Oct |
|
Chronic blockade of endothelin receptors improves ischemia-induced angiogenesis in rat hindlimbs through activation of vascular endothelial growth factor-no pathway. | 2001 Oct |
|
Endothelin mediates phospholipase C stimulation in the proximal tubule during initiation of compensatory renal growth in adult rats. | 2001 Oct |
|
Potent and selective ET-A antagonists. 1. Syntheses and structure-activity relationships of N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives. | 2001 Oct 11 |
|
Endothelin receptor blockade in congestive heart failure. | 2001 Oct 30 |
|
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. | 2001 Oct 6 |
|
Endothelin-receptor antagonists in pulmonary hypertension. | 2001 Oct 6 |
|
Report from the 93rd Cardiovascular and Renal Drugs Advisory Committee Meeting, August 9-10, 2001. | 2001 Oct 9 |
|
Endothelin involvement in respiratory centre activity. | 2001 Sep |
|
Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. | 2001 Sep |
|
Growth factors in idiopathic pulmonary fibrosis: relative roles. | 2002 |
|
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. | 2002 Apr |
|
Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. | 2002 Apr |
|
Bosentan (Tracleer) for pulmonary arterial hypertension. | 2002 Apr 1 |
|
Tracleer. Tablets ease symptoms of rare lung disorder. | 2002 Feb |
|
Medical management of primary pulmonary hypertension. | 2002 Feb |
|
Endothelin antagonists and heart failure. | 2002 Feb |
|
Crosstalk of endothelin-1 and platelet-derived growth factor in cardiac allograft arteriosclerosis. | 2002 Feb 20 |
|
Human endothelin subtype A receptor enhancement during tissue culture via de novo transcription. | 2002 Jan |
|
Direct left ventricular wall stretch activates GATA4 binding in perfused rat heart: involvement of autocrine/paracrine pathways. | 2002 Jan |
|
Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure. | 2002 Jan |
|
Hyperhexosemia induced functional and structural changes in the kidneys: role of endothelins. | 2002 Jan |
|
Naftidrofuryl exerts antiserotonergic but no endothelin-receptor blocking effects in AS4.1 cells, juxtaglomerular cells and isolated perfused rat kidneys. | 2002 Jan |
|
[The effects of endothelin blockade on renal expression of angiotensin II type 1 receptor in diabetic hypertensive rats]. | 2002 Jan 10 |
|
[Physical endurance improves markedly. New therapy approach in pulmonary hypertension]. | 2002 Jan 17 |
|
Tracleer (bosentan). | 2002 Jan-Feb |
|
[Bosentan in pulmonary hypertension]. | 2002 Mar |
|
Chronic endothelin receptor blockade prevents renal vasoconstriction and sodium retention in rats with chronic heart failure. | 2002 Mar |
|
Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. | 2002 Mar |
|
Bosentan enters market with risk management program. | 2002 Mar 15 |
|
Treatment of primary pulmonary hypertension -- the next generation. | 2002 Mar 21 |
|
Bosentan therapy for pulmonary arterial hypertension. | 2002 Mar 21 |
Sample Use Guides
Initiate at 62.5 mg twice daily with or without food for 4 weeks,
and then increase to 125 mg twice daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8637410
Curator's Comment: In vitro, bosentan inhibits the contractions of isolated rat trachea induced by
ET-1 in a concentration-dependent manner (1-100 uM). https://www.ncbi.nlm.nih.gov/pubmed/18729040
Competition studies show that, in the absence of human serum albumin, the IC50 value of Bosentan was 5.7 nM. Addition of increasing doses of human serum albumin incrementally decreased the potency of Bosentan to 122.7 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175581
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
||
|
WHO-VATC |
QC02KX01
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
||
|
FDA ORPHAN DRUG |
134200
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
||
|
LIVERTOX |
NBK547999
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
STAYVEER (AUTHORIZED SCLERODERMA, SYSTEMIC
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
||
|
WHO-ATC |
C02KX01
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
TRACLEER (AUTHORIZED: PLUMONARY HYPERTENSION, SYSTEMATIC SCLERODERMA)
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
||
|
FDA ORPHAN DRUG |
267608
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
||
|
FDA ORPHAN DRUG |
292209
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/03/139
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m2625
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
157212-55-0
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
Bosentan
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
185462
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
498193
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
ALTERNATIVE | |||
|
HH-16
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
1076115
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
SUB22249
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
Q326023R30
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
100000091512
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
3494
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
DTXSID80873178
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
BOSENTAN
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
51450
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
75207
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
392
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
Q326023R30
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
C086232
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
C47417
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
DB00559
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY | |||
|
CHEMBL957
Created by
admin on Fri Dec 15 15:33:54 GMT 2023 , Edited by admin on Fri Dec 15 15:33:54 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD